GlyCardial Diagnostics Overview
- Year Founded
-
2017
- Status
-
Out of Business
- Employees
-
7
- Latest Deal Type
-
Out of Business
GlyCardial Diagnostics General Information
Description
Developer of novel biomarkers intended to improve the early diagnosis of cardiac ischemic events to reduce the impact of the disease on patients' life. The company's biomarkers prevent irreversible myocardial damage and heart failure by helping in the early diagnosis of ischemia, enabling patients to avoid evolution after an ischemic event.
Contact Information
Website
www.glycardial.comCorporate Office
- Parc Científic De Barcelona
- Tower I, Floor 5, A08, Baldiri Reixac 4-8
- 08028 Barcelona
- Spain
Corporate Office
- Parc Científic De Barcelona
- Tower I, Floor 5, A08, Baldiri Reixac 4-8
- 08028 Barcelona
- Spain
GlyCardial Diagnostics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Out of Business | 14-Nov-2023 | Completed | Out of Business | |||
5. Early Stage VC | 30-Mar-2021 | Completed | Clinical Trials - General | |||
4. Grant | 27-Jan-2021 | Completed | Clinical Trials - General | |||
3. Early Stage VC | 10-Dec-2018 | Completed | Clinical Trials - General | |||
2. Grant | 05-Dec-2018 | $2.22M | $1.99M | Completed | Clinical Trials - General | |
1. Seed Round | 10-Nov-2017 | $1.99M | $1.99M | Completed | Startup |
GlyCardial Diagnostics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | 2,030 | $1.191768 | $587.1 | $587.1 | 1x | $587.1 | 25.93% |
GlyCardial Diagnostics Patents
GlyCardial Diagnostics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2022510403-A | Methods and compositions for the prevention and / or treatment of ischemic injury and ischemic reperfusion injury | Pending | 05-Dec-2018 | ||
EP-3890830-A2 | Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury | Inactive | 05-Dec-2018 | ||
JP-2022506108-A | Antibodies specific for glycosylated apoj and their use | Pending | 23-Oct-2018 | ||
CA-3115887-A1 | Antibodies specific for glycosylated apoj and uses thereof | Pending | 23-Oct-2018 | ||
AU-2019365391-A1 | Antibodies specific for glycosylated apoj and uses thereof | Inactive | 23-Oct-2018 | C07K16/30 |
GlyCardial Diagnostics Signals
GlyCardial Diagnostics FAQs
-
When was GlyCardial Diagnostics founded?
GlyCardial Diagnostics was founded in 2017.
-
Who is the founder of GlyCardial Diagnostics?
Lina Badimon Ph.D, Gemma Vilahur Ph.D, Teresa Padró, and Judit Cubedo Ph.D are the founders of GlyCardial Diagnostics.
-
Where is GlyCardial Diagnostics headquartered?
GlyCardial Diagnostics is headquartered in Barcelona, Spain.
-
What is the size of GlyCardial Diagnostics?
GlyCardial Diagnostics has 7 total employees.
-
What industry is GlyCardial Diagnostics in?
GlyCardial Diagnostics’s primary industry is Drug Discovery.
-
Is GlyCardial Diagnostics a private or public company?
GlyCardial Diagnostics is a Private company.
-
What is GlyCardial Diagnostics’s current revenue?
The current revenue for GlyCardial Diagnostics is
. -
How much funding has GlyCardial Diagnostics raised over time?
GlyCardial Diagnostics has raised $2.91M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »